PCSK9 promotes atherosclerosis progression through the FOXO3a autophagy signaling pathway - Takeaways - MDSpire

PCSK9 promotes atherosclerosis progression through the FOXO3a autophagy signaling pathway

  • By

  • Yuanjia Shi

  • Jing Zhang

  • Lina Dai

  • Jie Chen

  • Shijia Geng

  • Yan Niu

  • Chongyang Dong

  • Chenlei Li

  • Rujin Liu

  • Ningxia Zhao

  • Xiaomeng Wang

  • Zhanfeng Gao

  • Xi Yang

  • Shang Gao

  • June 15, 2026

  • 0 min

Share

  • 1

    PCSK9 modulates the autophagy pathway, influencing the progression of atherosclerosis through mechanisms involving FOXO3a.

  • 2

    COS significantly reduces PCSK9 expression and autophagy-related protein levels, slowing atherosclerotic plaque progression.

  • 3

    In macrophages, PCSK9 enhances autophagic flux and expression of autophagy-related proteins, contributing to autophagic injury.

  • 4

    The FOXO3a inhibitor JY2 significantly inhibits autophagy but does not significantly affect PCSK9 levels.

  • 5

    PCSK9 inhibitors may represent a new therapeutic strategy for treating atherosclerosis by regulating autophagy.

Original Source(s)

PCSK9 promotes atherosclerosis progression through the FOXO3a autophagy signaling pathway

  • by Yuanjia Shi, Jing Zhang, Lina Dai, Jie Chen, Shijia Geng, Yan Niu, Chongyang Dong, Chenlei Li, Rujin Liu, Ningxia Zhao, Xiaomeng Wang, Zhanfeng Gao, Xi Yang, Shang Gao

  • June 15, 2026

Related Content

Multidisciplinary management of Grade III circumferential mixed hemorrhoids in a patient with Marfan syndrome receiving long-term anticoagulation: a case report

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma